Moderna’s 177% Surge Has Investors Asking What Comes Next

Key Points

• Moderna shares surged 177% in a single day after its melanoma vaccine, developed with Merck, outperformed an existing standard immunotherapy in a late-stage trial.
• Heavy short interest of roughly 12% of Moderna's float fueled a short squeeze, as covering purchases amplified the rally and left short sellers with billions in paper losses.
• Despite the excitement, full trial data and regulatory approval, possibly not until 2027, are still pending, and shares dipped in Thursday's pre-market trading.

It's not every day that a company already worth billions sees its shares nearly triple in a single trading session. Welcome to the world of biotech, because that's exactly what happened to Moderna Inc. NASDAQ: MRNA on Wednesday of this week, after the Massachusetts-based company stunned the market with a breakthrough that sent its stock rocketing to a multi-year high.

The catalyst was a set of results from a closely watched trial of an experimental skin cancer vaccine, and the numbers were dramatic enough to reprice the company instantly. Shares closed up a remarkable 177% in a single day, adding to a rally that has seen the stock climb some 465% so far this year.

For a company whose fortunes had faded badly since its pandemic-era heyday, this is a stunning turn of events. So what exactly did Moderna announce, why has it electrified investors, and crucially, how much further might the shares have to run?

The Breakthrough Behind the Surge

At the heart of the excitement is a personalized cancer vaccine, developed by Moderna in partnership with the pharmaceutical giant Merck & Co. Inc. NYSE: MRK. The treatment is designed to combat melanoma, a serious form of skin cancer, and it uses the same messenger RNA (mRNA) technology that underpinned Moderna's COVID-19 vaccine.

The results themselves were seriously impressive. In a large late-stage trial of more than 1,100 high-risk patients, the vaccine, used in combination with Merck's blockbuster immunotherapy drug, meaningfully outperformed the latter’s drug used on its own. It reduced the risk of cancer returning and slowed its spread, marking the first time any late-stage trial has improved the established treatment in this setting.

That last point is what makes the news so significant. The existing drug is already a hugely successful therapy, so beating it is no small feat. For the many patients who undergo surgery for melanoma only to live in fear of a recurrence, a treatment that measurably lowers that risk represents a meaningful advance.

Why the Stock Reacted as It Did

The sheer scale of the share price move suggests the market saw this as far more than a single promising drug. The most important reason is that the result strongly validates Moderna's entire approach to fighting cancer with mRNA technology.

This is the crux of the bull case. The company has a whole pipeline of similar vaccines in development, targeting cancers of the lung, kidney, and bladder, among others. A convincing win in melanoma raises hopes that the same underlying technology could succeed across other programs, opening up a vast potential market far beyond this one disease.

The Short Squeeze That Poured Fuel on the Fire

Powerful as the science is, it also doesn't fully explain the scale of the single-session move. For that, you have to understand who was standing on the other side of the trade. Moderna had become a favorite target of short sellers, investors who borrow and sell a stock in the hope of buying it back cheaper later, profiting if the price falls.

In recent weeks, as much as 12% of Moderna’s entire float was being held by shorts, so when the trial news broke, and the stock erupted, all of those bearish positions were suddenly deep underwater. The only way to stop the losses mounting was to buy the shares back, and fast.

That stampede to exit their short positions, or to “cover,” is what turned yesterday’s big rally into an explosive one. As short sellers scrambled to buy, their purchases pushed the price higher still, forcing yet more of them to capitulate in a self-reinforcing spiral known as a short squeeze. By the end of the session, those betting against the company were reportedly sitting on paper losses approaching $5 billion, a brutal reminder of how quickly a crowded short can unravel.

How Much Further Could It Go

After a move of this magnitude, the natural question is whether the shares have further to climb, and here some caution is warranted. The full trial data have yet to be presented, and the treatment must still clear the lengthy path to regulatory approval, something management hopes could happen as early as 2027. A great deal of optimism looks to be baked into the price now, too.

Indeed, Moderna shares were trading lower in Thursday's pre-market session, surely a sign that some investors are starting to take profits. For those on the sidelines, the sensible course may be to watch how this plays out in the coming weeks and perhaps wait for the stock to consolidate before jumping in. Whatever way you play it, investors must remember all the while that biotech stocks can be brutally binary—capable of soaring on a single trial result like this one, but just as capable of slumping on the next.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source